Találati lista | Tudóstér

001-es BibID:	BIBFORM065574
Első szerző:	Nagy Noémi, M. (vegyész, angol szakfordító)
Cím:	SH2D1A and SLAM protein expression in human lymphocytes and derived cell lines / Noémi Nagy, Cristina Cerboni, Karin Mattsson, Akihiko Maeda, Péter Gogolák, János Sümegi, Árpád Lányi, LáSzló Székely, Ennio Carbone, George Klein, Eva Klein
Dátum:	2000
ISSN:	0020-7136
Megjegyzések:	he gene defect responsible for the X-linked lymphoproliferative disease (XLP) is associated with an impaired control of Epstein-Barr virus (EBV) infection. The gene has been recently identified and the encoded protein (designated SH2D1A, DSHP or SAP) was characterized. It is a 128 amino acid (aa) protein, containing a single Src homology 2 (SH2) domain. It interacts with signaling lymphocytic activation molecule (SLAM) expressed on the surface of activated T and B cells. We show that activated T, but not activated B, cells express the SH2D1A protein. NK cells express the protein as well. Tumor lines originating from B, T or NK cells exhibited similar SH2D1A protein expression as the corresponding normal cells, with some notable exceptions. EBV-carrying, tumor phenotype representative (type I), but not EBV-carrying lymphoblastoid cell line (LCL)-like (type III) or EBV-negative Burkitt lymphoma (BL) lines expressed SH2D1A. The phenotypic switch from type I to type III in the EBV-carrying BL line Mutu was associated with a down-regulation of SH2D1A and up-regulation of SLAM. In contrast to normal ex vivo and long-term activated NK cells, 2 of 3 NK leukemia lines expressed SLAM. All 3 lines expressed SH2D1A, like their normal counterparts.
Tárgyszavak:	Orvostudományok Elméleti orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
Megjelenés:	International Journal Of Cancer 88 : 3 (2000), p. 439-447. -
További szerzők:	Cerboni, Cristina Mattsson, Karin Maeda, Akihiko Gogolák Péter (1968-) (biológus, immunológus) Sümegi János Lányi Árpád (1962-) (biológus, immunológus) Székely László Carbone Ennio Klein, George Klein Éva
Internet cím:	Szerző által megadott URL Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Saját polcon:

001-es BibID:	BIBFORM065568
Első szerző:	Rajnavölgyi Éva (immunológus)
Cím:	A repetitive sequence of Epstein-Barr virus nuclear antigen 6 comprises overlapping T cell epitopes which induce HLA-DR-restricted CD4+ T lymphocytes / Éva Rajnavölgyi, Noémi Nagy, Britt Thuresson, Zsuzsa Dosztányi, Ágnes Simon, István Simon, Robert W. Karr, Ingemar Ernberg, Eva Klein, Kerstin I. Falk
Dátum:	2000
ISSN:	1460-2377
Megjegyzések:	Most human adults carry the Epstein-Barr virus (EBV) and develop immunological memory against the structural and the virus-encoded cellular proteins. The EBV nuclear antigen 6 (EBNA6) elicits cytotoxic T cell responses and it also maintains a persistent antibody response. The majority of sera from EBV-seropositive individuals reacts with a synthetic peptide, p63, comprising 21 amino acids of a repetitive region of EBNA6. CD4(+) T lymphocytes, with specificity for p63, could be recalled from the T cell repertoire of EBV carriers that expressed certain HLA-DR allotypes which were identified as good binders of p63 by an in vitro flow cytometric assay. Analysis of the HLA-DR/p63 interaction by molecular mechanics calculations indicated the presence of multiple overlapping epitopes which were predicted to bind in a HLA-DRB1 allo- and subtype-specific manner. Specific activation of p63-selected long-term CD4(+) T cell cultures resulted in a proliferative response, in the production of IL-2 and in the secretion of high levels of tumor necrosis factor as measured by bioassays. Proliferation and cytokine production of p63-specific T cells could be induced by p63-loaded HLA-DR-matched antigen-presenting cells and by B cells co-expressing relevant HLA-DR molecules and EBNA6. Our results show that peptides of an EBNA6 repeat region induce CD4(+) T cells which can react with EBNA6-carrying cells in many individuals. We suggest that these T(h) cells may be important in conditioning dendritic cells for initiation potent virus-specific immune responses, provide help for EBV-specific B cells, drive IgG isotype switch and support the sustained effector function of memory cytotoxic T lymphocytes.
Tárgyszavak:	Orvostudományok Elméleti orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban human CD4+ T lymphocyte HLA-DR-peptide interaction virus-specific interactions
Megjelenés:	International Immunology. - 12 : 3 (2000), p. 281-293. -
További szerzők:	Nagy Noémi, M. (1960-) (vegyész, angol szakfordító) Thuresson, Britt Dosztányi Zsuzsanna Simon Ágnes (1969-) (laboratóriumi szakorvos) Simon István Karr, Robert W. Ernberg, Ingemar Klein Éva Falk, Kerstin I.
Internet cím:	Szerző által megadott URL DOI Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Saját polcon:

001-es BibID:	BIBFORM050640
035-os BibID:	PMID:20837094
Első szerző:	Skribek, Henriette
Cím:	Chronic lymphoid leukemia cells are highly sensitive to the combination of prednisolone and daunorubicin, but much less to doxorubicin or epirubicin / Henriette Skribek, Rita Otvos, Emilie Flaberg, Noemi Nagy, Laszlo Markasz, Staffan Eksborg, Tamas Masszi, Andras Kozma, Emma Adam, Attila Miseta, Eva Klein, Laszlo Szekely
Dátum:	2010
ISSN:	0301-472X
Megjegyzések:	OBJECTIVE: To generate a comprehensive map of the drug sensitivity of chronic lymphoid leukemia cells (CLL) using a newly developed in vitro drug-sensitivity assay based on automated evaluation of cell viability on single-cell level. MATERIALS AND METHODS: Primary CLL cells from 77 patients were tested using automated digital fluorescence microscopy. The effect of 27 frequently used chemotherapeutic agents was measured in short-term fluorescence survival assay. To avoid typical in vitro artifacts such as growth factor depletion and oxidative damage, the cell were cultured in a novel, total human blood lysate-based medium (OmniSanguine) in order to preserve the composition of growth factor flora and redox conditions of the in vivo environment. RESULTS: CLL cells from different patients showed considerable heterogeneity in their drug-sensitivity patterns. This pattern was stable even after in vitro activation of cell proliferation. Half of the samples were sensitive to fludarabine and chlorambucil. Daunorubicin was the most potent drug. It was effective in 75 of 77 cases. In addition, daunorubicin and prednisolone showed a strong synergistic effect. CONCLUSIONS: We suggest that the combination of low-dose daunorubicin and prednisolone might be an additional treatment option for therapy-resistant cases of CLL.
Tárgyszavak:	Orvostudományok Gyógyszerészeti tudományok idegen nyelvű folyóiratközlemény külföldi lapban
Megjelenés:	Experimental Hematology. - 38 : 12 (2010), p. 1219-1230. -
További szerzők:	Ötvös Rita (1979-) (vegyész) Flaberg, Emilie Nagy Noémi, M. (1960-) (vegyész, angol szakfordító) Márkász László (1977-) (gyermekgyógyász) Eksborg, Staffan Masszi Tamás Kozma András Ádám Emma Miseta Attila Klein Éva Székely László
Internet cím:	Szerző által megadott URL DOI Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Saját polcon: